T2 Biosystems, Inc. (0A57.L)
| Previous close | 1.8450 |
| Open | 1.8293 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 1.7950 - 1.8293 |
| 52-week range | 1.7950 - 74.0800 |
| Volume | |
| Avg. volume | 1,849 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 10 Oct 2024 - 14 Oct 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireT2 Biosystems Highlights New Article Published in The Lancet: Changing the Culture of Blood Culture
LEXINGTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted a recently published article in The Lancet, a world-leading medical journal. The article titled “Changing the Culture of Blood Culture” was authored by Sally Davies, Richard A Marfuggi, Rick A Bright, Steve Brozak, and Michael Osterholm on September 20, 2024. “The T2 Biosystems team
- GlobeNewswire
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has successfully defended against an opposition filed against a key patent for its direct-from-whole blood detection method in the European Union. The opposition was filed in May 2023 with the European Patent Office (EPO) by bioMerieux and a strawman representing other undisclos
- GlobeNewswire
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
Expands available market to include over 200 children’s hospitals in the United StatesLEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its FDA-cleared T2Candida® Panel for pediatric patients. The Company expects to immediately begin marketing and
